273 related articles for article (PubMed ID: 35104792)
1. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
2. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
[TBL] [Abstract][Full Text] [Related]
4. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
5. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
6. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
[TBL] [Abstract][Full Text] [Related]
7. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
9. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
[TBL] [Abstract][Full Text] [Related]
10. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
11. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
12. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract][Full Text] [Related]
13. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
Park JW; Sahm F; Steffl B; Arrillaga-Romany I; Cahill D; Monje M; Herold-Mende C; Wick W; Turcan Ş
Neuro Oncol; 2021 Jan; 23(1):76-87. PubMed ID: 32882013
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
15.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
16. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
[TBL] [Abstract][Full Text] [Related]
17. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
18. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
Leu S; von Felten S; Frank S; Boulay JL; Mariani L
J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
[TBL] [Abstract][Full Text] [Related]
20. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
